Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2721346 | 0.78 | ALDH1A1 (0.64) | ALDH1A1NPSR1NOTUMKMT2ATSHR | |
| SCHEMBL12615992 | 0.76 | ALDH1A1 (0.68) | ALDH1A1NPSR1NOTUMKMT2ATSHR | |
| SCHEMBL481942 | 0.75 | ALDH1A1 (0.53) | ALDH1A1NPSR1NOTUMKMT2ATSHR | |
| SCHEMBL4203255 | 0.74 | ALDH1A1 (0.49) | ALDH1A1NPSR1NOTUMKMT2ATSHR | |
| SCHEMBL4202205 | 0.74 | ALDH1A1 (0.51) | ALDH1A1NPSR1TSHRKDM4EMAPT | |
| SCHEMBL4210503 | 0.72 | ALDH1A1 (0.46) | ALDH1A1NPSR1NOTUMKMT2ATSHR | |
| SCHEMBL4197409 | 0.72 | XDH (0.48) | ALDH1A1NPSR1NOTUMKMT2ATSHR | |
| SCHEMBL436604 | 0.72 | ALDH1A1 (0.58) | ALDH1A1NPSR1NOTUMKMT2ANPC1 | |
| SCHEMBL4207326 | 0.71 | ALDH1A1 (0.45) | ALDH1A1NPSR1NOTUMKMT2ATSHR | |
| Fluoride SCHEMBL28811107 | 0.70 | ALDH1A1 (0.56) | ALDH1A1NPSR1NOTUMKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977334-B2 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity modulator, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | TRIESELMANN THOMAS | 2008-09-25 | — | — | US | disclosed |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | ALDH1A1 674/4885NPSR1 167/4885NOTUM 1422/4885 |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | ALDH1A1 674/4885NPSR1 167/4885NOTUM 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.